Loading...
Docoh
Log in Free sign up

Enzo Biochem (ENZ)

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Company profile

Ticker
ENZ
Exchange
NYSE
Website
www.enzo.com
CEO
Elazar Rabbani
Employees
Incorporated
New York
Location
New York
Fiscal year end
Jul 31
Sector
Professional, Scientific, and Technical Services > Testing Laboratories
Industry (SIC)
Services - Medical Laboratories
Quest Diagnostics • Laboratory Corp. Of America • Akumin • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Centogene ...
SEC CIK
0000316253
Corporate docs
Subsidiaries
Enzo Clinical Labs, Inc. • Enzo Life Sciences, Inc. • Enzo Therapeutics, Inc. • Enzo Realty LLC • Enzo Realty II, LLC ...
IRS number
132866202

ENZ stock data

News

From Benzinga Pro
Enzo Biochem To Launch Monkeypox Testing Services This Week
11 Aug 22
Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for
Enzo Biochem Q3 EPS $(0.10) Down From $0.04 YoY, Sales $26.20M Down From $32.80M YoY
9 Jun 22
Enzo Biochem (NYSE:ENZ) reported quarterly losses of $(0.10) per share. This is a 350 percent decrease over earnings of $0.04 per share from the same period last year. The company reported $26.20 million in sales this
Earnings Scheduled For June 9, 2022
9 Jun 22
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report quarterly loss at $0.05 per share on revenue of $14.64 million.
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
5 Jun 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
3 Jun 22

Press releases

From Benzinga Pro
Enzo Biochem Appoints Matthew Kupferberg as General Counsel
3 Aug 22
NEW YORK, NY, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the
Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor
9 Jun 22
Third quarter revenue of $26.2 million declined sequentially and year over year due to the anticipated waning of COVID-19 volumes and the economic shutdowns in Asia Received approval from New York State Department of
UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
6 Jun 22
NEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June
Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
2 Jun 22

Calendar

9 Jun 22
16 Aug 22
31 Jul 23

Financial summary

Financial statements Chart ENZ financial data
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jul 21 Jul 20 Jul 19 Jul 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 32.13M 32.13M 32.13M 32.13M 32.13M 32.13M
Cash burn (monthly) (no burn) (no burn) 1.62M 1.12M 282.33K 617.67K
Cash used (since last report) n/a n/a 5.78M 3.99M 1.01M 2.21M
Cash remaining n/a n/a 26.35M 28.14M 31.12M 29.92M
Runway (months of cash) n/a n/a 16.3 25.2 110.2 48.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ENZ insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 22 Kara Cannon Common Stock, $0.01 Par Value Buy Acquire P No No 2.42 2,500 6.05K 2,500
12 Jul 22 Radoff Bradley Louis Common Stock, $0.01 Par Value Buy Acquire P No No 2.27 12,500 28.38K 4,194,663
12 Jul 22 Radoff Bradley Louis Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 4,236,329
12 Jul 22 Mary Tagliaferri Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 80,729
12 Jul 22 Ian B. Walters Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 80,729
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ENZ institutional ownership history Ownership history
37.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 50 61 -18.0%
Opened positions 3 11 -72.7%
Closed positions 14 15 -6.7%
Increased positions 12 9 +33.3%
Reduced positions 13 17 -23.5%
13F shares Current Prev Q Change
Total value 65.1M 88.23M -26.2%
Total shares 21.72M 27.07M -19.8%
Total puts 30.1K 49.4K -39.1%
Total calls 55.7K 44.1K +26.3%
Total put/call ratio 0.5 1.1 -51.8%
Largest owners Shares Value Change
Harbert Discovery Fund 5.18M $17.03M 0.0%
Renaissance Technologies 3.01M $8.73M -2.7%
Roumell Asset Management 2.39M $6.94M -1.8%
Vanguard 1.77M $5.14M -0.7%
Dimensional Fund Advisors 1.59M $4.62M -0.1%
BLK Blackrock 1.54M $4.47M +0.5%
VIEX Capital Advisors 1.44M $4.16M -17.3%
Fuller & Thaler Asset Management 951.24K $2.76M +0.5%
Boothbay Fund Management 539.95K $1.57M +69.0%
Potomac Capital Management 496.81K $1.44M +138.8%
Largest transactions Shares Bought/sold Change
Harbert Fund Advisors 0 -5.18M EXIT
AMH Equity 30K -566.74K -95.0%
MS Morgan Stanley 488.18K +469.27K +2482.5%
VIEX Capital Advisors 1.44M -300.96K -17.3%
Potomac Capital Management 496.81K +288.81K +138.8%
Boothbay Fund Management 539.95K +220.45K +69.0%
Renaissance Technologies 3.01M -83.6K -2.7%
Bridgeway Capital Management 375.4K +64.2K +20.6%
SNS Financial 62.5K +62.5K NEW
IVZ Invesco 0 -59.24K EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: consumed, cumulative, home, HRSA, independent, prevalence, requisition, responded, RSU, stipulation, volatility, Walter
Removed: automatic, automatically, began, begin, Charter, delayed, extended, falsely, letter, ongoing, opposition, planned, Proposed, repayment, reply, scheduled, significance, stated, submit, Supermajority, unrealized, Vote
From filing 10-Q 2022 Q3
Financial reports
View all
10-Q
2022 Q3
Quarterly report
9 Jun 22
10-Q
2022 Q2
Quarterly report
14 Mar 22
10-Q
2022 Q1
Quarterly report
15 Dec 21
10-K/A
2021 FY
Annual report (amended)
1 Dec 21
10-K/A
2021 FY
Annual report (amended)
29 Nov 21
10-K
2021 FY
Annual report
12 Oct 21
10-Q
2021 Q3
Quarterly report
11 Jun 21
10-Q
2021 Q2
Quarterly report
16 Mar 21
10-Q
2021 Q1
Quarterly report
11 Dec 20
10-K
2020 FY
Annual report
19 Oct 20
Current reports
View all
8-K/A
Material Modifications to Rights of Security Holders
6 May 22
8-K
Material Modifications to Rights of Security Holders
27 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
8 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
31 Mar 22
8-K
Enzo Biochem Announces Appointments of David Bench and Kara Cannon to New Executive Management Positions
30 Mar 22
8-K
Amendments to Articles of Incorporation or Bylaws
18 Mar 22
8-K
Departure of Directors or Certain Officers
7 Mar 22
8-K
Departure of Directors or Certain Officers
21 Jan 22
8-K
Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors
4 Jan 22
8-K
Departure of Directors or Certain Officers
18 Oct 21
Registration and prospectus
View all
S-8
Registration of securities for employees
9 Nov 21
S-8
Registration of securities for employees
15 Jan 21
S-8
Registration of securities for employees
6 Mar 20
S-8
Registration of securities for employees
12 Aug 18
S-3
Shelf registration
31 Aug 17
S-3/A
Shelf registration (amended)
27 Oct 16
S-3
Shelf registration
31 Aug 16
424B5
Prospectus supplement for primary offering
30 Dec 14
S-8
Registration of securities for employees
24 Jun 14
S-3
Shelf registration
31 Jul 13
Proxies
View all
DEFA14A
Additional proxy soliciting materials
6 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Apr 22
DEF 14A
Definitive proxy
28 Feb 22
PRER14A
Preliminary revised proxy
18 Feb 22
PRE 14A
Preliminary proxy
6 Jan 22
PREC14A
Preliminary proxy with contested solicitation
19 Nov 21
DFAN14A
Additional proxy materials by non-management
25 Oct 21
DFAN14A
Additional proxy materials by non-management
19 Oct 21
DFAN14A
Additional proxy materials by non-management
5 Jan 21
DFAN14A
Additional proxy materials by non-management
31 Dec 20
Other
View all
UPLOAD
Letter from SEC
28 Nov 21
UPLOAD
Letter from SEC
21 Jan 21
CORRESP
Correspondence with SEC
29 Dec 20
CORRESP
Correspondence with SEC
21 Dec 20
UPLOAD
Letter from SEC
16 Dec 20
UPLOAD
Letter from SEC
5 Mar 20
UPLOAD
Letter from SEC
13 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
UPLOAD
Letter from SEC
10 Feb 20
UPLOAD
Letter from SEC
19 Nov 19
Ownership
View all
4
ENZO BIOCHEM / Kara Cannon ownership change
19 Jul 22
4
ENZO BIOCHEM / MARY TAGLIAFERRI ownership change
14 Jul 22
4
ENZO BIOCHEM / Ian B. Walters ownership change
14 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
14 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
13 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
6 Jul 22
11-K
Annual report of employee stock purchases
24 Jun 22
4
ENZO BIOCHEM / Hamid Erfanian ownership change
17 Jun 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
16 Jun 22
4
ENZO BIOCHEM / David Bench ownership change
15 Jun 22

Patents

View all
Utility
Assays for Detecting Modified Compounds
3 Feb 22
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.
Utility
Pharmaceutical Compositions and Methods Targeting WNT Pathway Proteins
27 Jan 22
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213.
Utility
Immunomodulatory Pharmaceutical Compositions Including a Synthetic Peptide and Transforming Growth Factor Beta
27 Jan 22
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Utility
Fluorescence Quencher Polymer Conjugates and Uses Thereof
27 Jan 22
The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.
Utility
Assays for detecting modified compounds
23 Nov 21
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.

Transcripts

View all
2022 Q3
Earnings call transcript
10 Jun 22
2022 Q2
Earnings call transcript
15 Mar 22
2022 Q1
Earnings call transcript
16 Dec 21
2021 Q3
Earnings call transcript
10 Jun 21
2021 Q2
Earnings call transcript
16 Mar 21
2021 Q1
Earnings call transcript
10 Dec 20
2020 Q4
Earnings call transcript
13 Oct 20
2020 Q3
Earnings call transcript
8 Jun 20
2020 Q1
Earnings call transcript
10 Dec 19
2019 Q4
Earnings call transcript
15 Oct 19

Reddit threads

View all